Eli Lilly and Company (NYSE:LLY) Stock Holdings Raised by Fi3 FINANCIAL ADVISORS LLC

Fi3 FINANCIAL ADVISORS LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,917 shares of the company’s stock after purchasing an additional 33 shares during the period. Eli Lilly and Company makes up approximately 4.3% of Fi3 FINANCIAL ADVISORS LLC’s holdings, making the stock its 5th largest holding. Fi3 FINANCIAL ADVISORS LLC’s holdings in Eli Lilly and Company were worth $11,516,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in LLY. Virtu Financial LLC grew its stake in shares of Eli Lilly and Company by 11.6% during the fourth quarter. Virtu Financial LLC now owns 7,288 shares of the company’s stock valued at $5,626,000 after buying an additional 757 shares during the last quarter. Quantbot Technologies LP grew its stake in shares of Eli Lilly and Company by 52.8% during the fourth quarter. Quantbot Technologies LP now owns 5,741 shares of the company’s stock valued at $4,432,000 after buying an additional 1,984 shares during the last quarter. Sciencast Management LP bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $832,000. ZEGA Investments LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $1,349,000. Finally, Millstone Evans Group LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $840,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $839.44 on Friday. The stock has a market capitalization of $795.93 billion, a PE ratio of 71.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock’s 50 day simple moving average is $835.99 and its 200 day simple moving average is $839.87.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has initiated a share buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Bank of America reaffirmed a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a research note on Thursday, March 6th. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.